WO2003026603A1 - Association de principes actifs, en particulier de triterpenes et cyclodextrines, a usage cosmetique et/ou dermatologique - Google Patents

Association de principes actifs, en particulier de triterpenes et cyclodextrines, a usage cosmetique et/ou dermatologique Download PDF

Info

Publication number
WO2003026603A1
WO2003026603A1 PCT/EP2002/010042 EP0210042W WO03026603A1 WO 2003026603 A1 WO2003026603 A1 WO 2003026603A1 EP 0210042 W EP0210042 W EP 0210042W WO 03026603 A1 WO03026603 A1 WO 03026603A1
Authority
WO
WIPO (PCT)
Prior art keywords
cyclodextrin
polyethylene glycol
skin
weight
formulation according
Prior art date
Application number
PCT/EP2002/010042
Other languages
German (de)
English (en)
Inventor
Thomas Raschke
Timo Rode
Uwe SCHÖNROCK
Original Assignee
Beiersdorf Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beiersdorf Ag filed Critical Beiersdorf Ag
Publication of WO2003026603A1 publication Critical patent/WO2003026603A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/63—Steroids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/0208—Tissues; Wipes; Patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A61K8/046—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A61K8/06—Emulsions
    • A61K8/066—Multiple emulsions, e.g. water-in-oil-in-water
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A61K8/602—Glycosides, e.g. rutin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/738—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q1/00—Make-up preparations; Body powders; Preparations for removing make-up
    • A61Q1/02—Preparations containing skin colorants, e.g. pigments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/005—Preparations for sensitive skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/007—Preparations for dry skin

Definitions

  • the invention relates to preparations with extremely low so-called "stinging potential" and cosmetic or dermatological formulations which the skin - z. B. after sunbathing - take special care and reduce the skin's reactions to the effects of UV radiation.
  • Sericoside ie the (D) -glycosyl ester of 2 ⁇ , 3ß, 19 ⁇ , 24-tetrahydroxy-olean-12-en-28-carboxy acid
  • Sericoside ie the (D) -glycosyl ester of 2 ⁇ , 3ß, 19 ⁇ , 24-tetrahydroxy-olean-12-en-28-carboxy acid
  • Terminalia Sericea is part of the plant extract from Terminalia Sericea.
  • the termalia are large trees with hard wood, of which about 150 species occur in the tropics of all parts of the world.
  • Cyclodextrins are made up of 6, 7, 8 or even more ⁇ -1, 4-linked glucose units, the cyclohexaamylose ( ⁇ -cyclodextrin) being distinguished by the structure
  • Cycloheptaamylose (ß-cyclodextrin) is characterized by its structure
  • Cyclooctaamylose ( ⁇ -cyclodextrin) is characterized by its structure
  • Cycloenneaamylose ( ⁇ -cyclodextrin) is characterized by its structure
  • Cyclodextrins can also be propoxylated or methylated. Hydroxypropyl- ⁇ -cyclodextrin, hydroxypropyl- ⁇ -cyclodextrin and methyl- ⁇ -cyclodextrin are particularly important.
  • GB 1493926 describes certain pentacyclic triterpenes, also sericoside and its free carboxylic acid, as active pharmaceutical ingredients which can be incorporated into cosmetics and / or pharmaceutical preparations.
  • a use for the treatment of dermatological disorders is particularly useful.
  • the desirable use as an active ingredient encapsulated in cyclodextrins is not specifically disclosed.
  • the object of the present invention was to convert pentacyclic triterpenes, in particular sericoside, into cosmetic and / or dermatological ones Incorporate preparations so that the corresponding active ingredient is more bioavailable and can also be incorporated stably into the preparation.
  • the cyclodextrin content is 0.001-20.0% by weight, preferably 0.01-10.0% by weight, particularly preferably 0.1-5.0% by weight, based in each case the total weight of the composition is advantageous if the pentacyclic triterpenes or sericoside and / or sericoside-containing plant extracts are present, the content of pentacyclic triterpenes being selected from the range from 0.001 to 2% by weight, based on the total weight of the Preparation. It is advantageous if the mass ratio of cyclodextrin to sericoside is 1: 3 to 5: 1, preferably 2: 3 to 3: 1, particularly preferably 1: 1 to 2: 1.
  • the above-mentioned preparations can advantageously be in the form of solutions, emulsions of the water-in-oil (W / O) or oil-in-water (O / W) type, multiple emulsions, for example of the water-in-oil type. in water (W / O / W) or oil-in-water-in-oil (O / W / O), hydrodispersions or lipodispersions, gels, solid sticks or aerosols, particularly preferably in the form of a cream, a lotion, a cosmetic milk, an emulsion foam which can be removed from an aerosol container and an emulsion which serves as a soaking medium for wipes.
  • the invention also encompasses a cosmetic method for preventing and / or combating inflammatory skin conditions and / or skin protection in the case of sensitive, determined dry skin, and for caring for the skin after exposure to sunlight and / or for reducing the after-reaction of the skin to the action of UV radiation or a cosmetic method for immunostimulation of the skin, preferably for immunostimulation in the sense of treating injured skin, particularly preferably for treating wounds, characterized in that the formulation according to the invention is brought into contact with the affected area.
  • the active substance combinations according to the invention or cosmetic or dermatological preparations containing such active substance combinations are extremely satisfactory preparations in every respect. It was not foreseeable for the person skilled in the art that the preparations according to the invention
  • the active ingredient according to the invention or cosmetic or topical dermatological preparations with an effective content of the active ingredient according to the invention also serves in a surprising manner
  • laser and abrasive treatments serve the reduction of skin folds and scars to counteract the resulting skin irritation and to promote the regeneration processes in the injured skin.
  • the addition of at least one further cyclodextrin and / or cyclodextrin derivative, selected from the group of the native cyclodextrins ⁇ -, ⁇ - and ⁇ -cyclodextrin, is wholly or partly etherified and / or esterified and / or esterified on the hydroxyl groups differently derivatized ⁇ -, ⁇ - and ⁇ -cyclodextrins, in particular the hydroxypropyl- ⁇ -cyclodextrin, hydroxypropyl- ⁇ -cyclodextrin and the methyl- ⁇ -cyclodextrin.
  • a concentration of 0.001 to 20% and in particular of 0.1 to 5% by weight, based on the total weight of the preparation, of at least one cyclodextrin species and / or its derivatives is advantageous.
  • cyclodextrins and / or cyclodextrin derivatives to increase the solubility of sericoside is advantageous according to the invention.
  • cyclodextrins and / or cyclodextrin derivatives to improve the biological effectiveness of sericoside is also advantageous. It is particularly important that pentacyclic triterpenes contained in Terminalia sericea and cyclodextrins form host-guest compounds. These are the reason for the special properties of the preparations according to the invention.
  • thiols e.g. thioredoxin, Glutathione, cysteine, cystine, cystamine and their glycosyl, N-acetyl, methyl, ethyl, propyl, amyl, butyl and lauryl, palmitoyl, oleyi, ⁇ -linoleyl, cholesteryl and glyceryl esters ) and their salts, dilauryl thiodipropionate, distearyl thio dipropionate, thiodipropionic acid and their derivatives (esters, ethers, peptides, lipids, nucleotides, nucleosides and salts) as well as sulfoximine compounds (e.g.
  • buthionine sulfoximines in very low tolerable doses (e.g. pmol to ⁇ mol / kg), also (metal) chelators (e.g. ⁇ -hydroxy fatty acids, palmitic acid, phytic acid, lactoferrin), ⁇ -hydroxy acids (e.g.
  • citric acid citric acid, lactic acid, malic acid
  • humic acid bile acid
  • Biliary extracts bilirubin, biliverdin, EDTA, EGTA and their derivatives
  • unsaturated fatty acids and their derivatives e.g. ⁇ -linolenic acid, linoleic acid, oleic acid
  • folic acid and their derivatives ubiquinone and ubiquinol and their derivatives
  • vitamin C and derivatives e.g. ascorbyl palmitate, Mg ascorbyl phosphate, ascorbyl acetate
  • tocopherols and derivatives e.g.
  • vitamin E acetate
  • vitamin A and derivatives vitamin A palmitate
  • ⁇ -Lipoic acids ubiquinone, Q10 and ⁇ -glycosylrutin are particularly preferred.
  • the amount of the antioxidants (one or more compounds) in the preparations is preferably 0.001 to 30% by weight, particularly preferably 0.05 to 20% by weight, in particular 1 to 10% by weight, based on the total weight of the preparation ,
  • vitamin E and / or its derivatives represent the antioxidant (s)
  • vitamin A or vitamin A derivatives or carotenes or their derivatives represent the antioxidant or antioxidants, it is advantageous to determine their respective concentrations from the range from 0.001-10% by weight, based on the total weight of the formulation.
  • Medical topical compositions in the sense of the present invention generally contain one or more medicaments in an effective concentration.
  • medicaments in an effective concentration.
  • Preparations according to the invention can also advantageously contain substances which absorb UV radiation in the UVB range, the total amount of filter substances e.g. 0.1% by weight to 30% by weight, preferably 0.5 to 10% by weight, in particular 1.0 to 6.0% by weight, based on the total weight of the preparations, in order to produce cosmetic preparations To provide that protect the hair or skin from the entire range of ultraviolet radiation. They can also serve as a sunscreen for the hair.
  • the inorganic pigments are in hydrophobic form, i.e. that they have been treated to be water-repellent on the surface.
  • This surface treatment can consist in that the pigments are provided with a thin hydrophobic layer by methods known per se.
  • Such a method consists, for example, in that the hydrophobic surface layer according to a direction
  • n and m are stoichiometric parameters to be used at will, R and R 'are the desired organic radicals.
  • hydrophobized pigments shown in analogy to DE-OS 33 14 742 are advantageous.
  • Advantageous TiO 2 pigments are available, for example, under the trade names MT 100 T from TAYCA, M 160 from Kemira and T 805 from Degussa.
  • the prophylaxis or the cosmetic or dermatological treatment with the active ingredient used according to the invention or with the cosmetic or topical dermatological preparations with an effective content of active ingredient used according to the invention is carried out in the usual way, namely in such a way that the active ingredient used according to the invention or the cosmetic or topical dermatological preparations with an effective content of active ingredient used according to the invention is applied to the affected skin areas.
  • the active ingredient used according to the invention can advantageously be incorporated into customary cosmetic and dermatological preparations, which come in various forms can be present.
  • they can be a solution, an emulsion of the type water-in-oil (W / O) or of the type oil-in-water (O / W), or a multiple emulsions, for example of the type water-in-oil-in -Water (W / O / W) or oil-in-water-in-oil (O / W / O), a hydrodispersion or lipodispersion, a gel, a solid stick or an aerosol.
  • Oils such as triglycerides of capric or caprylic acid as well as natural oils such as e.g. Castor oil;
  • Silicone oils such as dimethylpolysiloxanes, diethylpolysiloxanes, diphenylpolysiloxanes and mixed forms thereof.
  • the oils are advantageously selected from the group of the esters from saturated and / or unsaturated, branched and / or unbranched alkane carboxylic acids with a chain length of 3 to 30 carbon atoms and saturated and / or unsaturated, branched and / or unbranched alcohols with a chain length of 3 to 30 carbon atoms, from the group of esters of aromatic carboxylic acids and saturated and / or unsaturated, branched and / or unbranched alcohols with a chain length of 3 to 30 carbon atoms.
  • any mixtures of such oil and wax components can also be used advantageously for the purposes of the present invention. It may also be advantageous to use waxes, for example cetyl palmitate, as the sole lipid component of the oil phase.
  • hydrocarbons paraffin oil, squalane and squalene can be used advantageously for the purposes of the present invention.
  • the oil phase can also contain cyclic or linear silicone oils or consist entirely of such oils, although it is preferred, in addition to the silicone oil or silicone oils, to have an additional content of other oil phase compounds.
  • Such silicones or silicone oils can be present as monomers, which are generally characterized by structural elements, as follows:
  • Cyclomethicone e.g. decamethylcyclopentasiloxane
  • silicone oils can also be used advantageously for the purposes of the present invention, for example undecamethylcyclotrisiloxane, polydimethylsiloxane, poly (methylphenylsiloxane), cetyldimethicone, behenoxydimethicone.
  • the aqueous phase of the preparations according to the invention optionally advantageously contains alcohols, diols or polyols of low C number, and also their ethers, preferably ethanol, isopropanol, propylene glycol, glycerol, ethylene glycol, ethylene glycol monoethyl or monobutyl ether, propylene glycol monomethyl, monoethyl or monobutyl ether , Diethy- glycol monomethyiV or - ⁇ monoethyl ether and analog products, further-alcohols of low carbon number, for example ethanol, isopropanol, 1, 2-propanediol, glycerol and in particular one or more thickening agents, which one or which can be advantageously selected from the group silicon dioxide , Aluminum silicates.
  • alcohols, diols or polyols of low C number and also their ethers, preferably ethanol, isopropanol, propylene glycol, g
  • Hydrocolloids These hydrocolloids can advantageously be selected from the aforementioned group.
  • Gums include plant or tree sap that harden in the air and form resins or extracts from aquatic plants. Gum arabic, locust bean gum, tragacanth, karaya, guar gum, pectin, gellan gum, carrageenan, agar, algine, chondrus, xanthan gum can advantageously be selected from this group for the purposes of the present invention.
  • derivatized gums such as e.g. Hydroxypropyl guar (Jaguar® HP 8).
  • polysaccharides and dehvates are e.g. Hyaluronic acid, chitin and chitosan, chondroitin sulfates, starch and starch derivatives.
  • cellulose derivatives are e.g. Methyl cellulose, carboxymethyl cellulose, hydroxyethyl cellulose, hydroxypropyl methyl cellulose.
  • Layered silicates contain naturally occurring and synthetic clays such as Montmorillonite, bentonite, hectorite, laponite, magnesium aluminum silicates such as Veegum®. These can be used as such or in a modified form such as e.g. Stearylalkonium hektorite.
  • silica gels can also advantageously be used.
  • the polyacrylates include e.g. Carbopol types from Goodrich (Carbopol 980, 981, 1382, 5984, 2984, ETD 2001, ETD 2020, ETD 2050, Ultrez 10 or Pemulen TR1 & TR2).
  • Carbopol types from Goodrich (Carbopol 980, 981, 1382, 5984, 2984, ETD 2001, ETD 2020, ETD 2050, Ultrez 10 or Pemulen TR1 & TR2).
  • polymers e.g. Polyacrylamides (Seppigel 305), polyvinyl alcohols, PVP, PVP / VA copolymers, polyglycols.
  • Preparations according to the invention in the form of emulsions contain one or more emulsifiers.
  • emulsifiers can advantageously be selected from the group of nonionic, anionic, cationic or amphoteric emulsifiers.
  • nonionic emulsifiers are those that are nonionic emulsifiers.
  • Partial fatty acid esters and fatty acid esters of polyhydric alcohols and their ethoxylated derivatives e.g. glyceryl monostearates, sorbitan stearates, glyceryl stearyl citrates, sucrose stearates
  • ethoxylated fatty alcohols and fatty acids e.g. glyceryl monostearates, sorbitan stearates, glyceryl stearyl citrates, sucrose stearates
  • alkylphenol polyglycol ether e.g. Triton X
  • Sugar derivatives esters and / or ethers of glucose, sucrose and other sugars; e.g. alkyl polyglucose such as polyglyceryl-3-methyl glucose distearate, methyl glucose sesquistearate)
  • soaps e.g. sodium stearate
  • amphoteric emulsifiers are amphoteric emulsifiers.
  • emulsifiers which include beeswax, wool wax, lecithin and sterols.
  • O / W emulsifiers can, for example, advantageously be selected from the group of the polyethoxylated or polypropoxylated or polyethoxylated and polypropoxylated products, e.g .:
  • RO - (- CH 2 -CH 2 -O-) n -CH 2 -COOH and n represent a number from 5 to 30,
  • alkyl ether sulfates of the general formula RO - (- CH 2 -CH 2 -O-) n -SO 3 -H
  • alkyl ether sulfates or the acids on which these sulfates are based of the general formula RO - (- CH 2 -CH (CH 3 ) -O-) n -SO 3 -H
  • the polyethoxylated or polypropoxylated or polyethoxylated and polypropoxylated O / W emulsifiers selected are particularly advantageously selected from the group of substances with HLB values of 11-18, very particularly advantageously with HLB values of 14.5-15. 5, provided the O ⁇ / V emulsifiers have saturated radicals R and R '. If the O W emulsifiers have unsaturated radicals R and / or R ', or if isoalkyl derivatives are present, the preferred HLB value of such emulsifiers can also be lower or higher.
  • fatty alcohol ethoxylates from the group of the ethoxylated stearyl alcohols, cetyl alcohols, cetylstearyl alcohols (cetearyl alcohols).
  • cetyl alcohols cetylstearyl alcohols
  • cetearyl alcohols cetearyl alcohols
  • Polyethylene glycol (12) lauryl ether (Laureth-12), polyethylene glycol (12) isolauryl ether (Isolaueth-12).
  • Sodium laureth-11 carboxylate can advantageously be used as the ethoxylated alkyl ether carboxylic acid or its salt.
  • Sodium laureth 1-4 sulfate can advantageously be used as alkyl ether sulfate.
  • Polyethylene glycol (30) cholesteryl ether can advantageously be used as the ethoxylated cholesterol derivative.
  • Polyethylene glycol (25) soyasterol has also proven itself.
  • polyethylene glycol (20) glyceryl laurate polyethylene glycol (21) glyceryl laurate
  • polyethylene glycol (22) glyceryl laurate polyethylene glycol (23) glyceryl laur
  • sorbitan esters from the group consisting of polyethylene glycol (20) sorbitan monolaurate, polyethylene glycol (20) sorbitan monostearate, polyethylene glycol (20) sorbitan monoisostearate, polyethylene glycol (20) sorbitan monopalmitate, polyethylene glycol (20) sorbitan monooleate.
  • W / O emulsifiers that can be used are: fatty alcohols with 8 to 30 carbon atoms, monoglycerol esters of saturated and / or unsaturated, branched and / or unbranched aikanecarboxylic acids with a chain length of 8 to 24, in particular 12 to 18 carbon atoms, diglycerol esters saturated and / or unsaturated, branched and / or unbranched aikanecarboxylic acids with a chain length of 8 to 24, in particular 12 - 18 C atoms, monoglycerol ethers saturated and / or unsaturated, branched and / or unbranched alcohols with a chain length of 8 to 24, in particular 12 - 18 C- Atoms, diglycerin ethers of saturated and / or unsaturated, branched and / or unbranched alcohols with a chain length of 8 to 24, in particular 12-18 C atoms, propylene glycol esters of saturated and / or unsaturated,
  • W / O emulsifiers are glyceryl stearate Glycerylmonoiso-, glyceryl monomyristate, glyceryl, diglyceryl monostearate, Diglycerylmono- isostearate, propylene glycol caprylate, propylene glycol monoisostearate, propylene glycol, propylene glycol, sorbitan, sorbitan, sorbitan monocaprylate, Sorbitanmonoisooleat, sucrose, cetyl alcohol, stearyl alcohol, Arachidyl alcohol, behenyl alcohol, isobehenyl alcohol, selachyl alcohol, chimyl alcohol, polyethylene glycol (2) stearyl ether (Steareth-2), glyceryl monolaurate, glyceryl monocaprinate, glyceryl monocaprylate.
  • Glycerol, panthenol, chitosan, fucogel, propylene glycol, dipropylene glycol, butylene glycol, mannitol, lactic acid can advantageously be used as skin moisturizers.
  • Glycerol, lactic acid, butylene glycol, urea, hyaluronic acid are particularly suitable.
  • the content of skin moisturizers is advantageously 1% by weight to 30% by weight, preferably 2 to 25% by weight, in particular 5 to 20% by weight, based on the total weight of the preparations.
  • Preparations according to the invention can also contain anionic, nonionic and / or amphoteric surfactants, especially if crystalline or microcrystalline solids, for example inorganic micropigments, are to be incorporated into the preparations according to the invention.
  • Surfactants are amphiphilic substances that can dissolve organic, non-polar substances in water.
  • hydrophilic parts of a surfactant molecule are mostly polar functional groups, for example -COO " , -OSO 3 2" , -SO 3 ⁇ , while the hydrophobic parts generally represent non-polar hydrocarbon radicals.
  • Surfactants are generally classified according to the type and charge of the hydrophilic part of the molecule. There are four groups:
  • the surface-active substance can be present in the preparations according to the invention in a concentration between 1 and 30% by weight, based on the total weight of the preparations.
  • Example 12 Gel cream or hydrodispersion

Abstract

L'invention concerne une formulation cosmétique et/ou dermatologique présentant une certaine teneur en cyclodextrines et triterpènes pentacycliques, notamment en séricoside.
PCT/EP2002/010042 2001-09-21 2002-09-07 Association de principes actifs, en particulier de triterpenes et cyclodextrines, a usage cosmetique et/ou dermatologique WO2003026603A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10146500A DE10146500A1 (de) 2001-09-21 2001-09-21 Kosmetische und/oder dermatologische Wirkstoffkombination
DE10146500.9 2001-09-21

Publications (1)

Publication Number Publication Date
WO2003026603A1 true WO2003026603A1 (fr) 2003-04-03

Family

ID=7699753

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/010042 WO2003026603A1 (fr) 2001-09-21 2002-09-07 Association de principes actifs, en particulier de triterpenes et cyclodextrines, a usage cosmetique et/ou dermatologique

Country Status (2)

Country Link
DE (1) DE10146500A1 (fr)
WO (1) WO2003026603A1 (fr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2414479A (en) * 2004-05-27 2005-11-30 Croda Int Plc Reactive cyclodextrins derivatised with proteins
WO2008037226A3 (fr) * 2006-09-27 2008-07-31 Univerzita Karlova V Praze Pri Procédé d'élaboration d'une préparation soluble de terpénoïdes tétra- et pentacycliques insolubles dans l'eau, préparation soluble d'un terpénoïde tétra- ou pentacyclique et composition pharmaceutique contenant cette préparation soluble
EP2363108A1 (fr) * 2010-03-02 2011-09-07 Neubourg Skin Care GmbH & Co. KG Formulation d'une mousse contenant au moins un triterpénoïde
WO2012058722A1 (fr) * 2010-11-03 2012-05-10 Cimtech Pty Limited Procédés et compositions pour maintenir et améliorer la santé de la peau
US9468590B2 (en) 2009-12-10 2016-10-18 Neubourg Skin Care Gmbh & Co. Kg Emulsifier-free, polymer-stabilized foam formulations
FR3095754A1 (fr) * 2019-05-10 2020-11-13 Pierre Fabre Dermo-Cosmetique Triterpènes pentacycliques dans le traitement du vitiligo
IT202200010646A1 (it) * 2022-05-23 2023-11-23 Giuliani Spa Forme di dosaggio per la somministrazione topica di triterpeni pentaciclici
RU2816950C2 (ru) * 2019-05-10 2024-04-08 Пьер Фабр Дермо-Косметик Пентациклические тритерпены в лечении витилиго

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1493926A (en) * 1974-01-29 1977-11-30 Inverni Della Beffa Spa Pentacyclic triterpenes obtainable from terminalia sericea and their derivatives
JPS61227517A (ja) * 1985-04-01 1986-10-09 Lion Corp 皮膚化粧料
EP0283713A2 (fr) * 1987-02-26 1988-09-28 INDENA S.p.A. Complexes de saponines avec des phospholipides et compositions pharmaceutiques et cosmétiques les contenant
JPH0358906A (ja) * 1989-07-28 1991-03-14 Shiseido Co Ltd 化粧料および粉末化粧料
JPH0372890A (ja) * 1989-08-11 1991-03-28 Nitto Denko Corp 植物エキスの製造方法
EP0555484A1 (fr) * 1990-11-21 1993-08-18 Hokkaidosugar Co., Ltd. Composition de triterpene pentacyclique, soluble dans l'eau, et production de cette composition
JPH09108261A (ja) * 1995-10-17 1997-04-28 Oji Paper Co Ltd 衛生生理用品
JPH09216810A (ja) * 1996-02-08 1997-08-19 Noevir Co Ltd 皮膚及び口腔用組成物
WO1999017736A1 (fr) * 1997-10-07 1999-04-15 Telos S.R.L. Produits a usage cosmetique et dermatologique obtenus par cobroyage
KR20000042127A (ko) * 1998-12-24 2000-07-15 유상옥 안정화시킨 비타민 c와 파이토스핑고신을 함유하는 피부보호화장료 조성물
DE10121090A1 (de) * 2001-04-26 2002-10-31 Beiersdorf Ag Wirkstoffkombinationen aus Tetrahydrocurcuminoiden und Sericosid und/oder Pflanzenextrakten

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4727064A (en) * 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
US5166139A (en) * 1987-02-26 1992-11-24 Indena, S.P.A. Complexes of saponins and their aglycons with phospholipids and pharmaceutical and cosmetic compositions containing them
US6267996B1 (en) * 1996-10-17 2001-07-31 Indena S.P.A Pharmaceutical and cosmetic formulations with antimicrobial activity

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1493926A (en) * 1974-01-29 1977-11-30 Inverni Della Beffa Spa Pentacyclic triterpenes obtainable from terminalia sericea and their derivatives
JPS61227517A (ja) * 1985-04-01 1986-10-09 Lion Corp 皮膚化粧料
EP0283713A2 (fr) * 1987-02-26 1988-09-28 INDENA S.p.A. Complexes de saponines avec des phospholipides et compositions pharmaceutiques et cosmétiques les contenant
JPH0358906A (ja) * 1989-07-28 1991-03-14 Shiseido Co Ltd 化粧料および粉末化粧料
JPH0372890A (ja) * 1989-08-11 1991-03-28 Nitto Denko Corp 植物エキスの製造方法
EP0555484A1 (fr) * 1990-11-21 1993-08-18 Hokkaidosugar Co., Ltd. Composition de triterpene pentacyclique, soluble dans l'eau, et production de cette composition
DE69112837T2 (de) * 1990-11-21 1996-05-23 Hokkaido Sugar Co Wasserlösliche pentacyclische triterpen-mischung sowie deren herstellung.
JPH09108261A (ja) * 1995-10-17 1997-04-28 Oji Paper Co Ltd 衛生生理用品
JPH09216810A (ja) * 1996-02-08 1997-08-19 Noevir Co Ltd 皮膚及び口腔用組成物
WO1999017736A1 (fr) * 1997-10-07 1999-04-15 Telos S.R.L. Produits a usage cosmetique et dermatologique obtenus par cobroyage
KR20000042127A (ko) * 1998-12-24 2000-07-15 유상옥 안정화시킨 비타민 c와 파이토스핑고신을 함유하는 피부보호화장료 조성물
DE10121090A1 (de) * 2001-04-26 2002-10-31 Beiersdorf Ag Wirkstoffkombinationen aus Tetrahydrocurcuminoiden und Sericosid und/oder Pflanzenextrakten

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; XP002229365, retrieved from STN Database accession no. 129:113411/DN, HCAPLUS *
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; XP002229366, retrieved from STN Database accession no. 116:11028/DN, HCAPLUS *
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; XP002229367, retrieved from STN Database accession no. 106:55658 *
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; XP002229368, retrieved from STN Database accession no. 127:52417/DN, HCAPLUS *
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; XP002229369, retrieved from STN Database accession no. 136:172517/DN, HCAPLUS *
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; XP002229370, retrieved from STN Database accession no. 115:90983/DN, HCAPLUS *
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; XP002229371, retrieved from STN Database accession no. 127:267835/DN, HCAPLUS *
KIM, KYOUNG-KOOK ET AL., YAKCHE HAKHOECHI, vol. 28, no. 1, 1998, pages 15 - 23 *

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2414479A (en) * 2004-05-27 2005-11-30 Croda Int Plc Reactive cyclodextrins derivatised with proteins
WO2008037226A3 (fr) * 2006-09-27 2008-07-31 Univerzita Karlova V Praze Pri Procédé d'élaboration d'une préparation soluble de terpénoïdes tétra- et pentacycliques insolubles dans l'eau, préparation soluble d'un terpénoïde tétra- ou pentacyclique et composition pharmaceutique contenant cette préparation soluble
CZ300722B6 (cs) * 2006-09-27 2009-07-22 Univerzita Karlova v Praze, Prírodovedecká fakulta Zpusob prípravy inkluzního komplexu pentacyklických a tetracyklických terpenoidu a farmaceutického prostredku obsahujícího tento inkluzní komplex, inkluzní komplex pentacyklického nebo tetracyklického terpenoidu a farmaceutický prostredek obsahující
JP2010504921A (ja) * 2006-09-27 2010-02-18 ウニヴェルジタ カルロヴァ ウ プラゼ，プリーロドヴェデカー ファクルタ 水不溶性の五環性テルペノイドおよび四環性テルペノイドの可溶性処方物の調製方法、五環性テルペノイドまたは四環性テルペノイドの可溶性処方物、およびこの可溶性処方物を含んだ薬学的組成物
US9468590B2 (en) 2009-12-10 2016-10-18 Neubourg Skin Care Gmbh & Co. Kg Emulsifier-free, polymer-stabilized foam formulations
EP2363108A1 (fr) * 2010-03-02 2011-09-07 Neubourg Skin Care GmbH & Co. KG Formulation d'une mousse contenant au moins un triterpénoïde
CN102883701A (zh) * 2010-03-02 2013-01-16 诺伊堡皮肤护理两合公司 包含至少一种三萜类化合物的泡沫制剂
WO2011107522A3 (fr) * 2010-03-02 2011-12-22 Neubourg Skin Care Gmbh & Co. Kg Formulations de mousse contenant au moins un triterpénoïde
CN102883701B (zh) * 2010-03-02 2016-10-26 诺伊堡皮肤护理两合公司 包含至少一种三萜类化合物的泡沫制剂
EA027038B1 (ru) * 2010-03-02 2017-06-30 Нойбург Скин Кэйр Гмбх & Ко. Кг Составы в виде пены, содержащие по меньшей мере один тритерпеноид
WO2012058722A1 (fr) * 2010-11-03 2012-05-10 Cimtech Pty Limited Procédés et compositions pour maintenir et améliorer la santé de la peau
FR3095754A1 (fr) * 2019-05-10 2020-11-13 Pierre Fabre Dermo-Cosmetique Triterpènes pentacycliques dans le traitement du vitiligo
WO2020229403A1 (fr) * 2019-05-10 2020-11-19 Pierre Fabre Dermo-Cosmetique Triterpènes pentacycliques dans le traitement du vitiligo
RU2816950C2 (ru) * 2019-05-10 2024-04-08 Пьер Фабр Дермо-Косметик Пентациклические тритерпены в лечении витилиго
IT202200010646A1 (it) * 2022-05-23 2023-11-23 Giuliani Spa Forme di dosaggio per la somministrazione topica di triterpeni pentaciclici
WO2023228079A1 (fr) * 2022-05-23 2023-11-30 Giuliani S.P.A. Formes posologiques pour l'administration topique de triterpènes pentacycliques

Also Published As

Publication number Publication date
DE10146500A1 (de) 2003-04-17

Similar Documents

Publication Publication Date Title
EP1174109B1 (fr) Préparations cosmétiques contenant des produits d'addition des cyclodextrines et de coenzyme Q 10
EP1511460A1 (fr) Preparation cosmetique et/ou dermatologique contenant des 2,3-dibenzyle-butyrolactones
EP1088547B1 (fr) Compositions cosmetiques contenant des adduits moléculaires de biotine et/ou de ses esters avec des cyclodextrines
WO2005053680A1 (fr) Association de 2,3-dibenzylbutyrolactone et de licochalcone-a
DE19943678A1 (de) Wirkstoffkombinationen aus oberflächenaktiven Citronensäureestern und Einschlußverbindungen von Cyclodextrinen und Retinoiden sowie kosmetische und dermatologische Zubereitungen mit einem Gehalt an solchen Gemischen
DE10229995A1 (de) Kosmetische oder dermatologische Zubereitungen mit einem Gehalt an alpha-Liponsäure
EP3009124A1 (fr) Utilisation de carnitine et/ou d'une ou plusieurs acyl-carnitines destinees a la fabrication de preparations dermatologiques ou cosmetiques pour la fabrication de preparation cosmetiques ou dermatologiques destinees a augmenter la biosynthese de ceramide
WO2002102338A1 (fr) Carnitine et acylcarnitines destinees au traitement et a la prophylaxie de defauts de pigmentation
WO2003026603A1 (fr) Association de principes actifs, en particulier de triterpenes et cyclodextrines, a usage cosmetique et/ou dermatologique
EP0908172A1 (fr) Formulations cosmétiques et dermatologiques de protection solaire sous forme d'émulsions H/E contenant des micropigments inorganiques hydrophobes et des tensioactifs hydrophiles
EP1216694A1 (fr) Combinaisons d'esters d'acide citrique tensioactifs et d'acide lipoique, ainsi que preparations cosmetiques et dermatologiques contenant de tels melanges
EP1367987A2 (fr) Utilisation de combinaisons d'agents actifs composees d'acide alpha-liponique et de substances dermatologiquement acceptables presentant une absorption de lumiere dans la gamme des uv-a et uv-b, pour la fabrication de preparations cosmetiques et dermatologiques
EP1449514A1 (fr) Préparations pour le soin de la peau contenant des rétinoides, des ubiquinones, et de la biotine ou de la carnitine
DE10161884A1 (de) Stabile wirkstoffhaltige Zubereitungen
DE10151245A1 (de) Kosmetische und/oder dermatologische Wirkstoffkombination
EP1392398A2 (fr) Preparation cosmetique et dermatologique destinee a la regulation et a l'elimination de sebum
DE10355711A1 (de) Kosmetische und dermatologische Emulsionen, enthaltend Kreatin und/oder Kreatinin und Elektrolytkonzentrationen, einer Ionenstärke von mindestens 50 mmol/l
DE10111048A1 (de) Verwendung von alpha-Liponsäure zur Herstellung kosmetischer oder dermatologischer Zubereitungen zur Regeneration beanspruchter Haut, insbesondere der gealterten Haut
DE10224298A1 (de) Kosmetische Stoffkombinationen
DE10233598A1 (de) Wirkstoffhaltige kosmetische und/oder dermatologische Zubereitung
DE10121090A1 (de) Wirkstoffkombinationen aus Tetrahydrocurcuminoiden und Sericosid und/oder Pflanzenextrakten
DE10146802A1 (de) Vitaminhaltige Hautpflegeprodukte
DE10207274A1 (de) Wirkstoffkombinationen aus Tetrahydrocurcuminoiden und alpha-Liponsäure
DE19903729A1 (de) Verwendung von oberflächenaktiven Citronensäureestern zur Stabilisierung von Retinoiden, synergistische Gemische aus Retinoiden und oberflächenaktiven Substanzen sowie kosmetische und dermatologische Zubereitungen mit einem Gehalt an solchen Gemischen
WO2003007909A2 (fr) Preparations cosmetiques ou medicales a effet rafraichissant durable

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): JP

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FR GB GR IE IT LU MC NL PT SE SK TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP